Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$1,000.

  • Relay Therapeutics' Capital Expenditures fell 100.44% to -$1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $636,000, marking a year-over-year decrease of 70.22%. This contributed to the annual value of $2.0 million for FY2024, which is 51.09% down from last year.
  • Per Relay Therapeutics' latest filing, its Capital Expenditures stood at -$1,000 for Q3 2025, which was down 103.85% from $26,000 recorded in Q2 2025.
  • Relay Therapeutics' Capital Expenditures' 5-year high stood at $2.8 million during Q1 2022, with a 5-year trough of -$1,000 in Q3 2025.
  • In the last 3 years, Relay Therapeutics' Capital Expenditures had a median value of $305,500 in 2024 and averaged $655,300.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 1,275.00% in 2021, then tumbled by 100.44% in 2025.
  • Over the past 5 years, Relay Therapeutics' Capital Expenditures (Quarterly) stood at $880,000 in 2021, then spiked by 163.18% to $2.3 million in 2022, then tumbled by 94.91% to $118,000 in 2023, then tumbled by 61.53% to $227,000 in 2024, then crashed by 100.44% to -$1,000 in 2025.
  • Its last three reported values are -$1,000 in Q3 2025, $26,000 for Q2 2025, and $384,000 during Q1 2025.